Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitra Hosing

Showing results (111-120 of 234) with videos related to

Pageof 24
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2010
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDSBorje S Andersson, Benigno C Valdez, Marcos de Lima, et al.
Bone Marrow Transplantation|October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantationMithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2008
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialMuzaffar H Qazilbash, Rima M Saliba, Yago Nieto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2012
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcomeYago Nieto, Uday Popat, Paolo Anderlini, et al.
British Journal of Haematology|June 20, 2008
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantationAmin M Alousi, Rima M Saliba, Grace-Julia Okoroji, et al.
Blood|January 27, 2009
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphomaConstantine S Tam, Roland Bassett, Celina Ledesma, et al.
Transplantation and Cellular Therapy|September 24, 2023
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative ConditioningJacinth Joseph, Samer A Srour, Denái R Milton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse CancersVivek Subbiah, Ravi Murthy, David S Hong, et al.
Cancer|October 15, 2016
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsElias Jabbour, Stefan Faderl, Koji Sasaki, et al.
Pageof 24

Showing results (111-120 of 234) with videos related to

Sort By:
Pageof 24
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2010
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDSBorje S Andersson, Benigno C Valdez, Marcos de Lima, et al.
Bone Marrow Transplantation|October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantationMithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalanBetul Oran, Sergio Giralt, Rima Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2008
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialMuzaffar H Qazilbash, Rima M Saliba, Yago Nieto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2012
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcomeYago Nieto, Uday Popat, Paolo Anderlini, et al.
British Journal of Haematology|June 20, 2008
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantationAmin M Alousi, Rima M Saliba, Grace-Julia Okoroji, et al.
Blood|January 27, 2009
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphomaConstantine S Tam, Roland Bassett, Celina Ledesma, et al.
Transplantation and Cellular Therapy|September 24, 2023
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative ConditioningJacinth Joseph, Samer A Srour, Denái R Milton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2018
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse CancersVivek Subbiah, Ravi Murthy, David S Hong, et al.
Cancer|October 15, 2016
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsElias Jabbour, Stefan Faderl, Koji Sasaki, et al.
Pageof 24